نتایج جستجو برای: capital assets pricing standard models capm

تعداد نتایج: 1477813  

ژورنال: حسابداری مالی 2020

Considering the inverse relationship between the value and momentum factors and the lack of simultaneous use of them in capital asset pricing models as well as non-use of stock quality as representative of profitability ans investment factors such as CAPM and Fama and French's three-factor models, the basis of this study is to provide a new functional model has been replacing pricing models o...

2006
Douglas J. Hodgson

The valuation of French Canadian paintings is analyzed empirically. Using a sample of auction prices for major French Canadian painters for the period 1968-2005, we run hedonic regressions to analyze the influence of various factors, including painter identity, on auction prices, as well as to construct a market price index. This index is used in a second stage analysis in which we analyze the ...

Journal: :Mathematics 2021

Students considering a masters in Finance Engineering or Artificial Intelligence are usually required to have an undergraduate background science, technology, engineering, mathematics (STEM). STEM students good capacity and but they may not studied financial theory. To facilitate the classroom teaching of Capital Asset Pricing Model (CAPM) for students, this paper seeks expound on essence theor...

Journal: :European Journal of Operational Research 2009
Carlo Alberto Magni

This paper focuses on inconsistencies arising from the use of NPV and CAPM for capital budgeting. It shows that (i) CAPM capital budgeting decision-making based on disequilibrium NPV is deductively inferred by the Capital Asset Pricing Model, (ii) the use of the disequilibrium NPV is widespread in finance both as a decision rule and as a valuation tool, (iii) the disequilibrium NPV does not gua...

2011
Alex Petkovic

In the estimation of portfolios, it is natural to assume that the utility function depends on exogenous variable.From this point of view, in this paper, we develop the estimation under the utility function depending on exogenous variable. To estimate the optimal portfolio, we introduce a function consists of mean and variance of the return process, the covariance of the return processes and the...

1997
Conway L. Lackman

It should not be surprising that in times of international monetary instability, there is renewed interest in the definition and analysis of exchange risk. One analytical framework that seems particularly suited to the analysis of the problem of exchange risk is the well-known Capital Asset Pricing Model (CAPM). CAPM is a two parameter, single period model focusing on the expected return of an ...

1998
NAI-FU CHEN RAYMOND KAN CHU ZHANG Kazumitsu Nawata Zhenyu Wang Guofu Zhou

It is a common practice to use t-ratios to select models in empirical asset pricing. In this paper, we show that such a practice could lead to the acceptance of very poor models. As an illustration, we examine a simple version of the widely used cross-sectional regression methodology and find analytically that variables with the highest t-ratios may not be highly correlated with expected return...

2003
Douglas J. Hodgson

The valuation of Canadian paintings is analyzed empirically. Using a sample of auction prices for major Canadian painters for the period 19682001, we run hedonic regressions to analyze the in‡uence of various factors, including painter identity, on auction prices, as well as to construct a market price index. This index is used in a second stage analysis in which we analyze the properties of Ca...

2006
Md. Mostafizur Rahman Md. Azizul Baten

Capital Asset Pricing Model (CAPM) provides an equilibrium linear relationship between expected return and risk of an asset. The purpose of this paper is to investigate a risk-return relationship within the CAPM framework. The study also aims at exploring whether CAPM is a good indicator of asset pricing in Bangladesh. For this study, a period 19992003 have been considered. Fama-French [1992] m...

Journal: :Health economics 2010
John A Vernon Joseph H Golec Joseph A Dimasi

In a widely cited article, DiMasi, Hansen, and Grabowski (2003) estimate the average pre-tax cost of bringing a new molecular entity to market. Their base case estimate, excluding post-marketing studies, was $802 million (in $US 2000). Strikingly, almost half of this cost (or $399 million) is the cost of capital (COC) used to fund clinical development expenses to the point of FDA marketing appr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید